Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue  Restrictive investment climate and low consumer confidence impact revenue and earnings performance   JENA, 6 August 2024 Carl Zeiss Meditec generated revenue of around €1,486.5m in the first nine months of fiscal year 2023/24 (prior year: €1,509.6m) corresp [ … ]

Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business   Jena, June 17, 2024 In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313 [ … ]

Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business   Jena, June 17, 2024 In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313 [ … ]

Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects  Planned reduction of stocks of surgical consumables in the Chinese distribution channel successfully completed JENA, 8 May 2024 Carl Zeiss Meditec generated revenue of around €947.2m in the first six months of fiscal year 2023/24 (prior [ … ]

Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects  Planned reduction of stocks of surgical consumables in the Chinese distribution channel successfully completed JENA, 8 May 2024 Carl Zeiss Meditec generated revenue of around €947.2m in the first six months of fiscal year 2023/24 (prior [ … ]

Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24  Decline in profit due to expected weaker product mix   JENA, 9 February 2024 Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%) [ … ]

   Carl Zeiss Meditec AG agrees to launch share buyback program with volume of up to €150m Jena, 29 January 2024 The Management Board of Carl Zeiss Meditec AG (ISIN: DE0005313704) has, with the approval of the Supervisory Board today, agreed to launch a share buyback program. Under the share buyback program, own shares will be purchased f [ … ]

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS   The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements. DUBLIN, CA (USA) / JENA, Germany | January 11, 2024 | Carl Zeiss Meditec AG ZEISS Medical Technology announced today tha [ … ]